Pharmaceutical News

RSS

Quest Diagnostics reports use of prescription opiates by American workers has increased by 40%

According to the American Council for Drug Education, more than 70 percent of substance abusers hold a job, which increases their risk of work related injury to them or others. While this statistic includes abuse of both legal and illegal drugs, Quest Diagnostics, a diagnostic testing company, reported the use of prescription opiates by American workers and job applicants has increased by 40% since 2005.

From Quest Diagnostics 22 Oct 2010

New multi-centre trial to treat cold and flu in children

Three Canadian research teams are trying to determine if a novel Canadian medicine approved by Health Canada for adults can help parents deal with the hacking coughs and runny noses their children suffer.

22 Oct 2010

Medivir reports consolidated net sales of SEK 54.7M

Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

22 Oct 2010

Diamyd Medical to divide operations into two business areas

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.

22 Oct 2010

Researchers analyze drugs' efficiency on influenza A virus

Beating the flu has always been tough, but it has gotten even more difficult in recent years. Two of the four antiviral drugs used to treat a nasty case of the influenza A virus no longer work.

22 Oct 2010

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases in its vaccine development efforts.

22 Oct 2010

Six government drug control laboratories in MENA to join USP to improve quality of drugs

Six government drug control laboratories in the Middle East and North Africa will join together with the United States Pharmacopeial Convention in an effort to improve their capabilities to test the quality of drugs. The MENA Regional Laboratory Network aims to promote communication and exchange of information among participating countries, strengthen the performance and technical skill of the laboratories and their personnel, harmonize methods that facilitate approval of drugs across countries in the region, and help eliminate substandard and counterfeit drugs.

22 Oct 2010

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Today, Cephalon, Inc. announced the signing of a convertible note subscription agreement with ChemGenex Pharmaceuticals Limited, an Australian-based oncology focused biopharmaceutical company.

22 Oct 2010

FDA announces new label for HIV antiviral drug Invirase

The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir), describing potentially life-threatening side effects on the heart when used with Norvir (ritonavir), another HIV antiviral medication.

22 Oct 2010

Hospira announces launch of piperacillin and tazobactam injection in the US

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the launch of piperacillin and tazobactam for injection in the United States. The medication is a generic version of Zosyn, the world's leading injectable antibiotic, from Pfizer. Piperacillin and tazobactam injection posted 2009 U.S. sales of more than $855 million.

22 Oct 2010

Drug payment database spurs local reports

A database put together by ProPublica of drugmakers' payments to physicians for promoting their products is now spurring local inquiries and garnering some response from physicians.

22 Oct 2010

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

$Medtronic's Xpander II receives FDA clearance for vertebral compression fractures$

Medtronic's Xpander II receives FDA clearance for vertebral compression fractures

Medtronic Inc. today announced Food and Drug Administration (FDA) clearance of the Kyphon Xpander II Inflatable Bone Tamp (IBT) for the treatment of vertebral compression fractures with minimally invasive Kyphon Balloon Kyphoplasty

22 Oct 2010

Neoprobe submits BLA response letter to FDA to commercialize RIGS technology

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has submitted a response letter to the U.S. Food and Drug Administration (FDA) regarding its RIGScan technology Biologic License Application (BLA).

22 Oct 2010

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

Daiichi Sankyo launches Inavir inhalation powder in Japan

Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan. Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.

22 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Mylan receives final FDA approval for Pramipexole Dihydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.

21 Oct 2010

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genmab A/S announced today that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010 were approximately DKK 78 million (approximately USD 14 million).

21 Oct 2010

New PharmaDeals v4 online resource to support pharmaceutical industry

In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.

21 Oct 2010